Results 201 to 210 of about 25,487 (238)
Some of the next articles are maybe not open access.
Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine, 2011Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily of cytokines which, in spite of being initially described as a strong anti-resorptive factor, has lately been considered as a possible link between bone and vascular disease.
A M, Blázquez-Medela +2 more
openaire +2 more sources
2003
Bone loss is associated with several diseases, most notably rheumatoid arthritis (RA). Focal bone erosions appear to be a very early feature of RA and are associated with disease severity and long-term functional impairment, making targeted therapy for focal bone erosion an important goal of treatment.
Pettit, A. R., Gravellese, E. M.
openaire +2 more sources
Bone loss is associated with several diseases, most notably rheumatoid arthritis (RA). Focal bone erosions appear to be a very early feature of RA and are associated with disease severity and long-term functional impairment, making targeted therapy for focal bone erosion an important goal of treatment.
Pettit, A. R., Gravellese, E. M.
openaire +2 more sources
Osteoprotegerin as a potential therapy for osteoporosis
Current Osteoporosis Reports, 2005The discovery and characterization of the RANKL/RANK/OPG signaling pathway and the identification of its role in the pathogenesis of bone loss have provided the rationale for the development of drugs with the ability to modulate RANK-induced osteoclastogenesis.
openaire +3 more sources
Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?
Current Pharmaceutical Design, 2014The OPG/RANK/RANKL axis is now recognized as a master regulator of bone remodeling, controlling osteoclast's maturation and extracellular matrix calcification. Nevertheless, a number of clinical and basic science studies conducted in the last few years demonstrated that the triad could be also involved in several physiological and pathological ...
Buso G +3 more
openaire +3 more sources
Osteoprotegerin and inflammation.
European cytokine network, 2003RANK, RANKL, and OPG have well established regulatory effects on bone metabolism. RANK is expressed at very high levels on osteoclastic precursors and on mature osteoclasts, and is required for differentiation and activation of the osteoclast. The ligand, RANKL binds to its receptor RANK to induce bone resorption.
N, Saidenberg Kermanac'h +4 more
openaire +1 more source
Osteoprotegerin in Primary Hyperparathyroidism
Hormone and Metabolic Research, 2014J, Szymczak, A, Bohdanowicz-Pawlak
openaire +2 more sources
Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr (−/−) Mice
Circulation, 2008Paul Kostenuik +2 more
exaly